CPT 81409 Drug Metabolism Genotyping Reimbursement | OpenPayer

Summary & Overview

CPT 81409: Drug Metabolism Genotyping Panel, Includes 2D6, 2C19, 2C9

CPT code 81409 represents a drug metabolism genotyping panel that includes testing for the 2D6, 2C19, and 2C9 genes. This laboratory procedure is increasingly important in clinical practice, as it helps physicians tailor drug therapies based on individual genetic profiles, improving medication safety and efficacy. The code is relevant for a range of specialties, including family medicine, internal medicine, and pathology, and is typically performed in independent laboratories.

Blue Cross Blue Shield is a key payer covered in this analysis. Readers will gain insight into the clinical context of drug metabolism genotyping, current billing practices, and policy updates related to laboratory services. The publication also provides benchmarks for utilization and reimbursement, as well as an overview of associated diagnoses and related CPT codes. Understanding the scope and application of CPT code 81409 is critical for stakeholders navigating the evolving landscape of precision medicine and laboratory billing.

Blue Cross Blue Shield81409drug metabolism genotypinglaboratory servicesprecision medicineclinical pathologyfamily medicineinternal medicinebilling codegenetic testingmedical policy

CPT Code Overview

CPT code 81409 is used for drug metabolism genotyping panels, which must include analysis of the 2D6, 2C19, and 2C9 genes by any method. This laboratory service is typically performed in an independent laboratory setting (Place of Service 81). Drug metabolism genotyping is essential for understanding how patients process various medications, enabling more personalized and effective treatment plans.

Clinical & Coding Specifications

Clinical Context

A patient is referred to an independent laboratory for drug metabolism genotyping. The ordering provider, such as a family medicine physician, internal medicine physician, or clinical pathologist, seeks to determine how the patient metabolizes certain medications. This is particularly relevant for patients who require therapeutic drug level monitoring, are on long-term drug therapy, or are being screened for genetic and chromosomal anomalies. The laboratory performs a genotyping panel that includes analysis of the CYP2D6, CYP2C19, and CYP2C9 genes, which are critical for drug metabolism. Results inform medication selection and dosing, especially for drugs metabolized by these enzymes. The workflow involves specimen collection, laboratory analysis, and reporting of results to the provider for clinical interpretation.

Coding Specifications

Modifiers:
- Modifier 26: Used when billing for the professional component of the laboratory service, such as interpretation of results by a physician or pathologist.
- Modifier TC: Used when billing for the technical component, which includes specimen processing and laboratory analysis.
Provider Taxonomies:

Code Specialty

National Reimbursement Benchmarks

For CPT code 81409, the national mean rate for Blue Cross Blue Shield and BUCA (average commercial) is $80.02. Medicare rates are not available in the input for this code, so a comparison between commercial and Medicare rates cannot be made.

Rate dispersion across payers is minimal, with the 25th, 50th, and 75th percentiles all at $80.00 for both Blue Cross Blue Shield and BUCA. This indicates a very tight range, with no variation between the lower and upper quartiles. The table and chart below present the full breakdown of national payer benchmarks for CPT code 81409.

81456 – Genomic sequence analysis panel (e.g., tumor or bone marrow), RNA alterations, 51 or more genes

81416-CYP2C19-CYTOCHROME-P450-FAMILY-2-SUBFAMILY-C-POLYPEPTIDE-19

81416 – CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *7, *8, *17)

81469-HEREDITARY-BREAST-CANCERRELATED-DISORDERS-EG-HEREDITARY

81469 – Hereditary breast cancer-related disorders (e.g., hereditary breast and ovarian cancer, hereditary breast cancer-related disorders), genomic sequence analysis panel, must include sequencing of at least 14 genes (e.g., ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53)

81447-TARGETED-GENOMIC-SEQUENCE-ANALYSIS-PANEL-SOLID-ORGAN

81447 – Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes

81408-TIER-2-MOLECULAR-PATHOLOGY-PROCEDURES-LEVEL

CPT 81408: Advanced Molecular Pathology Laboratory Procedure

81477-MOLECULAR-PATHOLOGY-PROCEDURE-LEVEL-9-EG-ANALYSIS-OF-1125

CPT 81477: Molecular Pathology Procedure, Level 9 DNA Sequence Analysis

81410-GENOMIC-SEQUENCING-PROCEDURE-HERITABLE-THORACIC-AORTIC

CPT 81410: Genomic Sequencing for Heritable Thoracic Aortic Disease

81419-GENOMIC-SEQUENCE-ANALYSIS-PANEL-SOLID-ORGAN-NEOPLASM-DNA

CPT 81419: Genomic Sequence Analysis Panel for Solid Organ Neoplasms

81476-CYP2C9-CYTOCHROME-P450-FAMILY-2-SUBFAMILY-C-POLYPEPTIDE-9

CPT 81476: CYP2C9 Gene Analysis for Drug Metabolism